Last edition
News about "Neurodegeneration Research at Novartis"
Novartis Expands Collaboration with BioArctic, Eyes Licensing Opportunity Worth Up to $772 Million
The partnership focuses on combining BioArctic’s BrainTransporter technology with a Novartis proprietary antibody to develop a novel drug candidate. Should Novartis proceed, it would take full responsibility for the candidate’s global development and commercialization.
Neurodegeneration Research At Novartis | 26/08/2025 | By Darshana | 127
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members